Dr THIERY-VUILLEMIN Antoine

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

Barthélémy P, Albigès L, Escudier B, Narciso B, Bigot P, Chehimi M, Emambux S, Calcagno F, Mouillet G, Eymard JC, Schlürmann F, Bailly S, Garbay D, Berdah JF, Palmaro MB, Goupil MG, Spaeth D, Néré S, Quentric C, Vano YA, Thiery-Vuillemin A

ESMO Open. 2024 06 18;9(7):103602

Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.

Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, Cawston H, Roiz J, Xiao Y, Solbes MN, Lambert P, Ravaud A, Loriot Y, Thiery-Vuillemin A, Lévy P

PLoS One. 2024 05 10;19(5):e0302548

Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.

Coquan E, Penel N, Lequesne J, Leman R, Lavaud P, Neviere Z, Brachet PE, Meriaux E, Carnot A, Boutrois J, Castera M, Goardon N, Muller E, Leconte A, Thiery-Vuillemin A, Clarisse B, Joly F

Ther Adv Urol. 2024 02 28;16:17562872241229876

Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.

Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, Escudier B, Flippot R, Albiges L

Eur J Cancer. 2024 02 3;201:113589

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.

Carneiro F, Vinceneux A, Larroquette M, Rony M, Carril L, Laguerre B, Blazevic I, Bartelemy P, Teyssonneau D, Goujon M, Linassier C, Thiery-Vuillemin A, Roubaud G, Mourey L, Albiges L, Gravis G, Gross-Goupil M, Cancel M

Eur J Cancer. 2024 01 15;199:113534

[Onco-nephrology: Origins, organization and perspectives].

Delaye M, Bay JO, Thiery-Vuillemin A, Isnard-Bagnis C

Bull Cancer. 2024 ;111(7-8):661-662

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in and/or in the PROfound Trial.

Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M

J Clin Oncol. 2023 11 14;:JCO2300339

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C

JAMA Oncol. 2023 10 26;:

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.

Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G

Eur Urol Oncol. 2023 10 7;:

Evaluation of local control after percutaneous microwave ablation versus partial nephrectomy: A propensity score matched study.

Panhelleux M, Balssa L, David A, Thiery-Vuillemin A, Kleinclauss F, Frontczak A

Prog Urol. 2023 10 3;:

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.

Sridhar SS, Powles T, Climent Durán MÁ, Park SH, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB, Gupta S, Petrylak DP, Bellmunt J, Wang J, Laliberte RJ, di Pietro A, Costa N, Grivas P, Sternberg CN, Loriot Y

Eur Urol. 2023 09 13;:

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang YH, Lee JL, Haas N, Sawrycki P, Sarwar N, Gross-Goupil M, Thiery-Vuillemin A, Mahave M, Kimura G, Perini RF, Saretsky TL, Bhattacharya R, Xu L, Powles T

Oncologist. 2023 08 17;:

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.

Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K

J Manag Care Spec Pharm. 2023 07;29(7):758-768

Management of cancer treatments in hemodialysis patients.

Matte P, Bihan K, Isnard-Bagnis C, Zahr N, Thiery-Vuillemin A, Gougis P, Campedel L

Bull Cancer. 2023 03 15;:

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C

Eur J Cancer. 2023 01 13;182:66-76

[A 2022 inventory in oncology news].

Bay JO, Bouleuc C, Caux C, Delom F, Firmin N, Gandemer V, L'Allemain G, Magné N, Orbach D, Robert J, Rodrigues M, Sabatier R, Thiery-Vuillemin A, Wislez M,

Bull Cancer. 2022 12 16;:

Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting.

Mauge L, Phan L, Benhamouda N, Galy-Fauroux I, Badoual C, Topart D, Thiery-Vuillemin A, Le Moulec S, Guillot A, Cessot A, Mejean A, Albiges L, Tartour E, Fournier L, Helley D, Oudard S

Clin Oncol (R Coll Radiol). 2022 12 14;:

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.

Coquan E, Clarisse B, Lequesne J, Brachet PE, Nevière Z, Meriaux E, Bonnet I, Castera M, Goardon N, Boutrois J, Travers R, Joly F, Grellard JM, Thiery-Vuillemin A

BMC Cancer. 2022 11 24;22(1):1213

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.

Meynard L, Dinart D, Delaunay B, Fléchon A, Saldana C, Lefort F, Gravis G, Thiery-Vuillemin A, Cancel M, Coquan E, Ladoire S, Maillet D, Rolland F, Boughalem E, Martin S, Laramas M, Crouzet L, Abbar B, Falkowski S, Pouessel D, Roubaud G

Eur J Cancer. 2022 09 8;175:43-53

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.

Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW

Lancet Oncol. 2022 09 2;:

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F

NEJM Evid. 2022 09;1(9):EVIDoa2200043

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK,

Lancet Oncol. 2022 09;23(9):1133-1144

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.

Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA

Clin Cancer Res. 2022 08 31;:OF1-OF11

Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study.

Escudier B, de Zélicourt M, Bourouina R, Nevoret C, Thiery-Vuillemin A

Clin Genitourin Cancer. 2022 07 24;:

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.

Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P

Eur Urol Oncol. 2022 07 16;:

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L

Clin Genitourin Cancer. 2022 07 10;:

Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?

Antoun C, Choffel L, Frontczak A, Gross-Goupil M, Thiery-Vuillemin A

Bull Cancer. 2022 06 15;:

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Loriot Y, Texier M, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K

Eur Urol. 2022 05 19;:

Impact of blood transfusion on survival after nephrectomy for localized or locally advanced renal cancer.

Détrée P, Balssa L, Richard V, Francois C, Barkatz J, Bernardini S, Chabannes E, Guichard G, Thiery-Vuillemin A, Kleinclauss F, Frontczak A

Prog Urol. 2022 May 3;:

Emergence of new strategies in metastatic kidney cancer: Emergence des nouvelles stratégies dans le cancer du rein métastatique.

Thiery-Vuillemin A

Bull Cancer. 2022 05;109(2S):2S1-2S3

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life).

Kaddissi AE, Ducleon GG, Lefort F, Mezepo G, Frontczak A, Goujon M, Mouillet G, Almotlak H, Gross-Goupil M, Thiery-Vuillemin A

Bull Cancer. 2022 05;109(2S):2S19-2S30

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A,

Lancet. 2022 Apr 8;:

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.

Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval JB, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M, Ruffion A, Renard-Penna R, Mathieu R, Sargos P, Rouprêt M, Ploussard G, Roubaud G, On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie

J Clin Med. 2022 Mar 21;11(6):

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-lab

Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F

Lancet Oncol. 2022 Feb 11;:

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.

Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, Castel-Ajgal Z, Bennamoun M, Campedel L, Thiery-Vuillemin A, Coquan E, Crouzet L, Berdah JF, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-Goupil M, Vano YA, Thibault C, Oudard S

J Oncol. 2022 ;2022:3449660

[A 2021 inventory in oncology news].

Bay JO, Bouleuc C, Firmin N, Gandemer V, Magne N, Orbach D, Penel N, Rodrigues M, Thiery-Vuillemin A, Wislez M, L'Allemain G, Sabatier R, Robert J,

Bull Cancer. 2021 Dec 31;:

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.

Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC

Cancers (Basel). 2021 Nov 20;13(22):

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K

Eur J Cancer. 2021 Nov 2;159:87-97

[Academic carriers in oncology and radiotherapy: Update for the readers of Bulletin du Cancer].

Calais G, Classe JM, Ducreux M, Hennequin C, Joly F, Karayan-Tapon L, Antoni D, Capitain O, Céraline J, Péron J, Tabouret E, Thiery-Vuillemin A

Bull Cancer. 2021 Sep 20;:

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T,

N Engl J Med. 2021 08 19;385(8):683-694

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Oudard S, Laguerre B, Gross-Goupil M, Bernhard JC, Colas S, Albiges L, Lebret T, Treluyer JM, Timsit MO, Escudier B

Eur Urol. 2021 Jun 26;:

FGFR alterations in urothelial carcinoma: Picking the right target.

Hubert P, Selmani Z, Loriot Y, Thiery-Vuillemin A

Bull Cancer. 2021 May 17;:

Post hoc health-related quality of life analysis according to response among patients with prostate cancer in the PROSELICA and FIRSTANA studies.

Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Ozatilgan A, Poole EM, Eisenberger M, de Bono J

Oncologist. 2021 Apr 27;:

Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.

Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, Hennequin C, Morgans AK, Geoffrois L, Limat S, Thiery-Vuillemin A, Nerich V

Clin Genitourin Cancer. 2021 Apr 5;:

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J

ESMO Open. 2021 Mar 16;6(2):100089

We need randomised studies to improve our knowledge on nutritional interventions for advanced cancer patients.

Bouleuc C, Marchal T, Chvetzoff G, Raynard B, Thiery-Vuillemin A, Aubry R

Oncologist. 2021 Jan 10;:

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.

Albiges L, Fléchon A, Chevreau C, Topart D, Gravis G, Oudard S, Tourani JM, Geoffrois L, Meriaux E, Thiery-Vuillemin A, Barthélémy P, Ladoire S, Laguerre B, Perrot V, Billard A, Escudier B, Gross-Goupil M

Eur J Cancer. 2020 Nov 27;142:102-111

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J,

N. Engl. J. Med.. 2020 Sep 20;:

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.

Mouillet G, Efficace F, Thiery-Vuillemin A, Charton E, Van Hemelrijck M, Sparano F, Anota A

Cancer Med. 2020 Aug 26;:

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V

Cancer Immunol. Immunother.. 2020 Jul 16;:

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L

Eur. J. Cancer. 2020 Jul 9;136:76-83

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.

Gassian N, Frontczak A, Mouillet G, Vernerey D, Manseur O, Goujon M, Meurisse A, Berthod D, Robert E, Calcagno F, Thiery-Vuillemin A

Bull Cancer. 2020 Jun;107(5S):eS16-eS21

[Systemic treatment of locally advanced or metastatic penile cancer].

Gassian N, Frontczak A, El Kaddissi A, Calcagno F, Almotlak H, Barkatz J, Mouillet G, Maurina T, Stein U, Nguyen Tan Hon T, Murez T, Thiery-Vuillemin A

Bull Cancer. 2020 Jun;107(5S):S17-S23

[Updates in onco-urology: academic research is a key factor].

Thiery-Vuillemin A

Bull Cancer. 2020 Jun;107(5S):S2-S4

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.

Klajer E, Garnier L, Goujon M, Schlurmann-Constans F, Mery B, Nguyen Tan Hon T, Mouillet G, Calcagno F, Thiery-Vuillemin A

Semin. Oncol.. 2020 May 26;:

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M

N. Engl. J. Med.. 2020 Apr 28;:

Impact on Health-Related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: Results from a Randomized Controlled Trial.

Bouleuc C, Anota A, Cornet C, Grodard G, Thiery-Vuillemin A, Dubroeucq O, Crétineau N, Frasie V, Gamblin V, Chvetzoff G, Favier L, Tournigand C, Grach MC, Raynard B, Salas S, Capodano G, Pazart L, Aubry R

Oncologist. 2020 Mar 25;:

[2019 international oncology news: A compendium].

Magné N, Sabatier R, Wislez M, André T, Rodrigues M, Hervé L, Thiery-Vuillemin A, Penel N, Bouleuc C, Bay JO

Bull Cancer. 2020 Feb 10;:

Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Werle P, Balssa L, Geoffrois L, Leblanc L, Albigès L, di Nunno V, Bensalah K, Ladoire S, Gravis G, Barthélémy P

Eur. Urol.. 2020 Jan 3;:

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero JM, Laguerre B, Thibault C, Hans S, Oudard S

Eur. J. Cancer. 2019 Nov 28;:

Metronomic cyclophosphamide induces regulatory T cells depletion and PSA specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O

Int. J. Cancer. 2019 Nov 20;:

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.

Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A,

Eur. Urol.. 2019 Oct 5;:

[Radiotherapy of oligometastases: Sequences and interactions with systemic therapies, example of kidney cancer].

Wespiser M, Goujon M, Nguyen Tan Hon T, Maurina T, Kleinclauss F, Créhange G, Thiery-Vuillemin A

Cancer Radiother. 2019 Oct 4;:

[Relapse surveillance of patients with testicular germ cell tumor].

Orillard E, Klajer E, Kalbacher E, Joly F, David A, Hervé L, Viot J, Mouillet G, Barkatz J, Kleinclauss F, Thiery-Vuillemin A

Bull Cancer. 2019 Sep 5;:

[Side effects of chemotherapy for testicular cancers and post-cancer follow-up].

Joly F, Ahmed-Lecheheb D, Thiery-Vuillemin A, Orillard E, Coquan E

Bull Cancer. 2019 Jun 3;:

[Oligometastatic prostate cancer management].

Kleinclauss F, Thiery-Vuillemin A

Prog. Urol.. 2019 Jun;29 Suppl 1:S20-S34

[Sexual dysfunctions of patients treated with orchidectmoy, chemotherapy and retroperitoneal lymphadenectomy, need for systematic andrological care?]

Barkatz J, Kleinclauss F, Rigaud J, Bouchot O, Orillard É, Thiery-Vuillemin A, Mouillet G, Kalbacher E, Madec FX

Bull Cancer. 2019 May 21;:

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, Vernerey D, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A

Health Qual Life Outcomes. 2019 Feb 4;17(1):25

Mery B, Thiery-Vuillemin A, Massard C, Albiges L, Magné N

Bull Cancer. 2018 Dec;105 Suppl 3:S219-S220

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S

Eur Urol Oncol. 2018 Dec;1(6):467-475

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.

Cholley T, Thiery-Vuillemin A, Limat S, Hugues M, Calcagno F, Mouillet G, Anota A, Nerich V

Clin Genitourin Cancer. 2018 Nov 7;:

[Cytoreduction nephrectomy: No future?]

Balssa L, Kleinclauss F, Almotlak H, Thiery-Vuillemin A

Bull Cancer. 2018 Nov;105(11):981-984

Impact of BRCA status on outcomes and survival in high-risk early breast cancers.

Klajer E, Paget-Bailly S, Meynard G, Meurisse A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Montcuquet P, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Populaire C, Collonge-Rame MA, Gligorov J, Curtit E, Pivot X, Mansi L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii68

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B

N. Engl. J. Med.. 2018 Jun 3;:

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of

Mouillet G, Paillard MJ, Maurina T, Vernerey D, Nguyen Tan Hon T, Almotlak H, Stein U, Calcagno F, Berthod D, Robert E, Meurisse A, Thiery-Vuillemin A

Trials. 2018 Apr 12;19(1):221

Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.

Thiery-Vuillemin A, Cholley T, Calcagno F, Hugues M, Maurina T, Limat S, Nguyen Tan Hon T, Almotlak H, Mouillet G, Nerich V

Clin Genitourin Cancer. 2018 Apr;16(2):e297-e305

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.

Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Antoni L, Lukac M, Van Sanden S, Pissart G, Reid A

ESMO Open. 2018 ;3(5):e000397

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Fizazi K, Ulys A, Sengeløv L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Guida A, Bellmunt J, Climent MA, Chowdhury S, Dumez H, Matouskova M, Penel N, Liutkauskiene S, Stachurski L, Sternberg CN, Baton F, Germann N, Daugaard G

Ann. Oncol.. 2017 Nov 1;28(11):2741-2746

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O

J. Clin. Oncol.. 2017 Oct 1;35(28):3189-3197

Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B

Cancer Chemother. Pharmacol.. 2017 Apr;:

[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté].

Dénommé F, Kroemer M, Montcuquet P, Nallet G, Thiery-Vuillemin A, Bazan F, Mouillet G, Villanueva C, Demarchi M, Stein U, Almotlak H, Chaigneau L, Curtit E, Meneveau N, Maurina T, Dobi E, Hon TN, Cals L, Mansi L, Verlut C, Pana-Katatali H, Caubet M, Paillard MJ, Limat S, Pivot X, Nerich V

Bull Cancer. 2016 Oct;103(10):849-860

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F

Cancer Treat. Rev.. 2016 Sep;:

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K

J. Clin. Oncol.. 2016 Sep 1;34(25):3005-13

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Calcagno F, Mouillet G, Adotevi O, Maurina T, Nguyen T, Montcuquet P, Curtit E, Kleinclauss F, Pivot X, Borg C, Thiery-Vuillemin A

Med. Oncol.. 2016 Aug;33(8):89

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O

Cancer Res.. 2016 Jul;76(14):4100-12

Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.

Mansi L, Demarchi M, Bazan F, Delroeux D, Chaigneau L, Thiery-Vuillemin A, Bernhard S, Lakkis Z, Lakkis Z, Nerich V, Pivot X, Kalbacher E

Int. J. Gynecol. Cancer. 2016 Feb;26(2):261-7

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study.

Caubet M, Dobi E, Pozet A, Almotlak H, Montcuquet P, Maurina T, Mouillet G, N'guyen T, Stein U, Thiery-Vuillemin A, Fiteni F

Mol Clin Oncol. 2015 Nov;3(6):1208-1212

[In Process Citation].

Laclergerie F, Mouillet G, Larre S, Eschwege P, Hubert J, Saussine C, Cormier L, Thiery-Vuillemin A, Kleinclauss F

Prog Urol. 2015 Nov;25(13):855-6

Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.

Thiery-Vuillemin A, Theodore C, Jacobasch L, Schmitz J, Papandreou C, Guillot A, Emmanouilides C, Slimane K, Kelkouli N, Kim S, Nguyen Tan Hon T

Clin Genitourin Cancer. 2015 Jun;13(3):231-8

[Impact of obesity on pathologic outcomes and biochemical reccurence after radical prostatectomy].

Balssa L, Pastori J, Lillaz J, Panouilleres M, Guichard G, Bernardini S, Chabannes E, Bittard H, Thiery-Vuillemin A, Kleinclauss F

Prog Urol. 2015 Apr 16. pii: S1166-7087(15)00101-3

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C

Oncologist. 2015 Mar 20. pii: theoncologist.2014-0198.

[Neoadjuvant before surgery treatments: state of the art in prostate cancer].

Richard V, Paillard MJ, Mouillet G, Lescut N, Maurina T, Guichard G, Montcuquet P, Martin L, Kleinclauss F, Thiery-Vuillemin A

Prog Urol. 2014 Jul;24(9):595-607

[Existence of pattern 5 on radical prostatectomy: poor prognostic factor associated with a lower biochemical recurrence-free survival].

Pastori J, Balssa L, Lillaz J, Guichard G, Chabannes E, Bernardini S, Bittard H, Thiery-Vuillemin A, Kleinclauss F

Prog Urol. 2014 Jun;24(7):433-40

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.

Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A

Onco Targets Ther. 2014 Feb 27;7:365-74

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.

Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X

Target Oncol. 2013 Jun;8(2):137-43

[Treatment of bladder outlet obstruction in locally advanced prostate cancer].

Martin L, Thiery-Vuillemin A, Kleinclauss F

Prog. Urol.. 2013 May;23(6):386-8

Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.

Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS, Demarchi M, Pivot X, Limat S

J Oncol Pharm Pract. 2013 Mar;19(1):8-17

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C

Clin Colorectal Cancer. 2013 Mar;12(1):28-36

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.

Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A

Clin Med Insights Oncol. 2013;7:1-12

Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.

Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, Succi C, Nguyen T, Kim S, Montcuquet P, Pivot X, Royer B

Ann Oncol. 2012 Nov;23(11):2992-3

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O

Bull Cancer. 2012 Jul;99 Suppl 1:S57-65

Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.

Curtit E, Chaigneau L, Pauchot J, Nguyen T, Nerich V, Bazan F, Thiery-Vuillemin A, Demarchi M, Pivot X, Villanueva C

Anticancer Res.. 2012 Apr;32(4):1481-3

Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.

Villanueva C, Chaigneau L, Dufresne A, Thierry Vuillemin A, Stein U, Demarchi M, Bazan F, N'guyen T, Pivot X

Breast. 2011 Aug;20(4):329-33

Cabazitaxel: a novel microtubule inhibitor.

Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X

Drugs. 2011 Jul 9;71(10):1251-8

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, Demarchi M, Bazan F, Sautiere JL, Maisonnette-Lescot Y, Ringenbach F, Bontemps P, Pivot X

Breast. 2011 Jun;20(3):284-7

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C

J. Clin. Oncol.. 2011 Apr;29(12):e330-2

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.

Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L, Villanueva C, Bazan F, Montcuquet P, Maisonnette-Escot Y, Sautiere JL, Algros MP, Pivot X

Breast. 2011 Feb;20(1):46-9

Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.

Thiery-Vuillemin A, Dobi E, Nguyen T, Royer B, Montange D, Maurina T, Kalbacher E, Bazan F, Villanueva C, Demarchi M, Chaigneau L, Ivanaj A, Pivot X

Anticancer Drugs. 2010 Nov;21(10):958-62.

Safety profile of new anticancer drugs.

Mansi L, Thiery-Vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X

Expert Opin Drug Saf. 2010 Mar;9(2):301-17.

Ixabepilone: a new active chemotherapy in the treatment of breast cancer.

Villanueva C, Vuillemin AT, Demarchi M, Bazan F, Chaigneau L, Pivot X

Womens Health (Lond Engl). 2009 Mar;5(2):115-21.

Anticancer therapy in patients with porphyrias: evidence today.

Thiery-Vuillemin A, Chaigneau L, Meaux-Ruault N, Villanueva C, N'guyen T, Maurina T, Stein U, Lorgis V, Demarchi M, Pivot X

Expert Opin Drug Saf. 2008 Mar;7(2):159-65.

A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

Viel E, Demarchi MF, Chaigneau L, Nguyen T, Legat C, Stein U, Thiery-Vuillemin A, Limat S, Pivot X, Borg C

Am J Clin Oncol. 2008 Feb;31(1):89-94.